Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drug Des Devel Ther
Asıl Yazarlar: Moussa, Mohamad, Papatsoris, Athanasios, Abou Chakra, Mohamed, Dellis, Athanasios
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2021
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7886109/
https://ncbi.nlm.nih.gov/pubmed/33603337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S240854
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller